¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"subcutaneous fat necrosis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • bacillary necrosis
    ¸·´ë±Õ±«»ç
  • coagulation necrosis
    ÀÀ°í±«»ç
  • colliquative necrosis
    ¾×È­±«»ç
  • cortical necrosis
    °ÑÁú±«»ç, ÇÇÁú±«»ç
  • cystic medial necrosis
    ³¶¼ºÁß°£¸·±«»ç
  • caseous necrosis
    Ä¡Á»ç
  • central hemorrhagic necrosis
    Áß½ÉÃâÇ÷±«»ç
  • central necrosis
    Á߽ɱ«»ç
  • centrilobular necrosis
    Á߽ɼҿ±±«»ç
  • fibrinoid necrosis
    ¼¶À¯¼Ò¸ð¾ç±«»ç, ÇǺ기¸ð¾ç±«»ç
  • gangrenous necrosis
    ±«Àú±«»ç
  • ischemic necrosis
    ÇãÇ÷±«»ç
  • lipolytic necrosis
    Áö¹æ¿ëÇØ±«»ç
  • liquefaction necrosis
    ¾×È­±«»ç
  • mummification necrosis
    ¹Ì¶óÈ­±«»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • caseous necrosis
    Ä¡Á»ç, °Ç¶ô±«»ç
  • central hemorrhagic necrosis
    Áß½ÉÃâÇ÷±«»ç
  • centrilobular necrosis
    Á߽ɼҿ±±«»ç
  • coagulation necrosis
    ÀÀ°í±«»ç
  • colliquative necrosis
    ¾×È­±«»ç
  • cortical necrosis
    °ÑÁú±«»ç
  • cystic medial necrosis
    ³¶¼ºÁßÃþ±«»ç
  • fibrinoid necrosis
    ¼¶À¯¼Ò¼º±«»ç
  • tumor necrosis factor
    Á¾¾ç±«»çÀÎÀÚ
  • gangrenous necrosis
    ±«Àú±«»ç
  • ischemic necrosis
    (¢¡coagulation necrosis) ÀÀ°í±«»ç
  • lipolytic necrosis
    Áö¹æ¿ëÇØ±«»ç
  • liquefaction necrosis
    (¢¡colliquative necrosis) ¾×È­±«»ç
  • massive hepatic necrosis
    ±¤¹üÀ§°£±«»ç
  • medial necrosis
    (¢¡medionecrosis) Áß°£¸·±«»ç
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • subcutaneous reaction
    ÇÇÇϹÝÀÀ(ù«ù»Úãëë)
  • subcutaneous sarcoid
    ÇÇÇÏÀ¯À°Á¾
  • subcutaneous synovial bursa
    ÇǺιØÁÖ¸Ó´Ï, ÇÇÇÏȰ¾×³¶(¡­üÁäûÒ¥).
  • subcutaneous synovial bursa
    ÇǺιØÁÖ¸Ó´Ï
  • subcutaneous tenotomy
    ÇÇÇÏ °ÇÀý¼ú (¡­Ëòôîâú).
  • subcutaneous tissue
    ÇǺιØÁ¶Á÷, ÇÇÇÏÁ¶Á÷ (ù«ù»ðÚòÄ).
  • subcutaneous tissue
    ÇǺιØÁ¶Á÷
  • subcutaneous tissue
    ÇÇÇÏÁ¶Á÷
  • subcutaneous transfusion
    ÇÇÇϼöÇ÷(ù«ù» âÃúì).
  • subcutaneous trochanteric bursa
    ´ëÅðÅ«µ¹±âÇǺιØÁÖ¸Ó´Ï, ÀüÀÚ°ñÇÇÇÏȰ¾×³¶.
  • subcutaneous vaccination
    ÇÇÇÏÁ¾µÎ¹ý (¡­ðúÔãÛö).
  • subcutaneous venous plexus
    ÇǺιØÁ¤¸Æ¾ó±â
  • subcutaneous wound
    ÇÇÇÏâ(ÇÇÇÏâ).
  • subcutaneous wound
    ÇÇÇÏâ(ù«ù»óÜ)
  • subcutis => subcutaneous tissue
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
NS   1) Nephrotic Syndrome
    1. Proteinuria
   &nb...
CR calculation rate; calculus removed; calorie-restricted; cardiac rehabilitation; cardiac resuscitatio...
FAT family attitudes test; fluorescent antibody technique; fluorescent antibody test
FES family environment scale; fat embolism syndrome; flame emission spectroscopy; forced expiratory spir...
FF degree of fineness of abrasive particles; fat-free; father factor; fecal frequency; fertility factor...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
FAT Fatty acid translocase
FAT Fluorescent Antibody Test
FAT Fluorescent antibody technique
HFD High Fat Diet
HMFG Human milk fat globule
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
epiphysial aseptic necrosis Aseptic necrosis of bony epiphyses, probably due to ischemia; it may affect the upper end of the femur (Legg-Calve-Perthes disease), the tibial tubercle (Osgood-Schlatter disease), the tarsal navicular bone or the patella (Kohler's disease), the second metatarsal head (Freiberg's disease), vertebral bodies (Scheuermann's disease), or the capitellum of the humerus (Panner's disease).
(05 Mar 2000)
tumor necrosis factor <cytokine> Originally described as a tumour inhibiting factor in the blood of animals exposed to bacterial lipopolysaccharide or Bacille Calmette-Guerin.
Preferentially kills tumour cells in vivo and in vitro, causes necrosis of certain transplanted tumours in mice and inhibits experimental metastases. Human Tumour Necrosis factor alpha is a protein of 157 amino acids and has a wide range of pro inflammatory actions. Usually considered a cytokine.
Synonym: cachectin.
Acronym: TNF
(13 Nov 1997)
tumour necrosis factor <cytokine> Originally described as a tumour inhibiting factor in the blood of animals exposed to bacterial lipopolysaccharide or Bacille Calmette-Guerin.
Preferentially kills tumour cells in vivo and in vitro, causes necrosis of certain transplanted tumours in mice and inhibits experimental metastases. Human Tumour Necrosis factor alpha is a protein of 157 amino acids and has a wide range of pro inflammatory actions. Usually considered a cytokine.
Synonym: cachectin.
Acronym: TNF
(13 Nov 1997)
tumour necrosis factor-beta <cytokine> A cytolytic factor that is produced by CD4 and CD8 T-cells after their exposure to an antigen.
(05 Mar 2000)
kidney cortex necrosis The death of all the functioning renal cells of the kidney cortex with continued viability of the majority of the medullary units. It is due usually to the arterial distribution peculiar to the kidney which makes the renal cortex more susceptible to diminished blood flow.
(12 Dec 1998)
kidney papillary necrosis A form of acute kidney disease characterised by necrosis of the renal papillae. It is most frequently associated with diabetes mellitus because of the severe vascular disease present in the arteries and capillaries, particularly in the kidney. There is usually a large component of infection present, and in non-diabetics pyelonephritis and obstructive uropathy are the usual aetiologic agents.
(12 Dec 1998)
kidney tubular necrosis, acute Acute kidney failure resulting from destruction of tubular epithelial cells. It is commonly attributed to exposure to toxic agents or renal ischemia following severe trauma.
(12 Dec 1998)
Zenker's necrosis A form of severe hyaline degeneration or necrosis in skeletal muscle, occurring in severe infections.
Synonym: waxy degeneration, Zenker's necrosis.
(05 Mar 2000)
zonal necrosis Necrosis predominantly affecting or limited to an anatomical zone, especially parts of the hepatic lobules defined according to proximity to either the portal tracts or central (hepatic) veins.
(05 Mar 2000)
femur head necrosis Aseptic or avascular necrosis of the femoral head. The major types are idiopathic (primary), as a complication of fractures or dislocations, and legg-perthes disease.
(12 Dec 1998)
fibrinoid necrosis Necrosis in which the necrotic tissue has some staining reactions resembling fibrin and becomes deeply eosinophilic, homogenous, and refractile.
(05 Mar 2000)
focal necrosis Occurrence of numerous, relatively small or tiny, fairly well-circumscribed, usually spheroidal portions of tissue that manifest coagulative, caseous, or gummatous necrosis and are characteristically associated with agents that are haematogenously disseminated; frequently observed only in histologic sections, but the foci may be as large as 1 to 3 mm and macroscopically visible; arbitrarily, foci larger than that are usually not termed focal necrosis.
(05 Mar 2000)
laminar cortical necrosis The breaking down of a definite cell layer in the cerebral cortex, encountered typically after temporary cardiac arrest or perinatal hypoxia.
(05 Mar 2000)
liquefactive necrosis A type of necrosis characterised by a fairly well-circumscribed, microscopically or macroscopically visible lesion that consists of the dull, opaque or turbid, gray-white to yellow-gray, soft or boggy, partly or completely fluid remains of tissue that became necrotic and was digested by enzymes, especially proteolytic enzymes liberated from disintegrating leukocytes; it is classically observed in abscesses, and frequently in infarcts of the brain.
(05 Mar 2000)
abdominal wall fat pad biopsy <investigation, procedure, surgery> The removal of a small specimen of the abdominal wall fat pad for microscopic examination. Often used in the diagnosis of amyloidosis. Performed with a local anaesthetic.
(25 Jun 1999)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á